CUMBERLAND PHARMACEUTICALS INC CPIX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-0.86
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $44.5M | -$2.8M | — | $4.8M | $24.5M |
| 2024 | $37.9M | -$6.5M | — | -$678,647 | $22.5M |
| 2023 | $39.6M | -$6.3M | — | $5.8M | $29.3M |
| 2022 | $42.0M | -$5.6M | — | $8.4M | $36.0M |
| 2021 | $36.0M | -$3.5M | — | $4.2M | $42.6M |
| 2020 | $37.4M | -$3.3M | — | $5.3M | $46.9M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.86 (distress)
- Working capital / assets 0.004
- Retained earnings / assets -0.349
- EBIT / assets -0.036
- Equity / liabilities 0.469
Source: SEC EDGAR filings · CIK 0001087294 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.